Patty Murray (D-WA) (Graeme Sloan/Sipa USA)(Sipa via AP Images)

Sen­ate user fee reau­tho­riza­tion bill omits ac­cel­er­at­ed ap­proval re­forms, shows wide gaps with House ver­sion

The Sen­ate health com­mit­tee on Tues­day re­leased its first ver­sion of the bill to reau­tho­rize all the dif­fer­ent FDA user fees. But un­like the House ver­sion, there are on­ly a few con­tro­ver­sial items in the Sen­ate’s ver­sion, which does not ad­dress ei­ther ac­cel­er­at­ed ap­proval re­forms or clin­i­cal tri­al di­ver­si­ty (as the House did).

While it’s still rel­a­tive­ly ear­ly in the process of fi­nal­iz­ing this leg­is­la­tion (the ul­ti­mate statu­to­ry dead­line is the end of Sep­tem­ber), the House and Sen­ate, at least ini­tial­ly, ap­pear to be start­ing off in dif­fer­ent cor­ners on what should be in­clud­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.